Effects of beta 1- vs. beta 1 + beta 2-blockade on exercise endurance and muscle metabolism in humans. 1989

J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
Division of Clinical Pharmacology, Toronto Western Hospital, Ontario, Canada.

The effects of beta-blockade on muscle utilization of glycogen and triglycerides, as well as potassium metabolism, were studied in eight healthy male subjects performing long-duration exercise to exhaustion. Subjects were studied after treatment with either placebo (PLAC), beta 1-selective (atenolol, 100 mg/day, AT), or nonselective beta-blockade (nadolol, 80 mg/day, NAD) each for 1 wk according to a randomized, double-blind, cross-over design. NAD and AT caused identical decreases in exercise heart rates, but endurance (71 +/- 8 min with PLAC) decreased significantly more with NAD (-33 +/- 4%) than with AT (-14 +/- 6%). Muscle glycogen breakdown, taking exercise time into account, was unaffected by treatment. In contrast, muscle triglyceride utilization was completely blocked by NAD whereas it was unchanged with AT as compared to PLAC. Adipose tissue lipolysis was inhibited to a similar extent by the two beta-blockers. Serum potassium increased to higher levels at exhaustion and muscle potassium decreased to lower levels with NAD than with AT or PLAC. These results suggest that decreased utilization of muscle triglycerides combined with lack of an enhanced glycogenolysis to compensate as well as alterations in potassium metabolism contribute to the decreased exercise capacity with nonselective beta-blockade compared with beta 1-selective blockade.

UI MeSH Term Description Entries
D008297 Male Males
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009248 Nadolol A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor. Corgard,SQ-11725,Solgol,SQ 11725,SQ11725
D010807 Physical Endurance The time span between the beginning of physical activity by an individual and the termination because of exhaustion. Endurance, Physical,Physical Stamina,Stamina, Physical
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006003 Glycogen
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
January 1995, Journal of applied physiology (Bethesda, Md. : 1985),
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
May 1986, Journal of applied physiology (Bethesda, Md. : 1985),
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
June 1984, Zeitschrift fur Kardiologie,
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
January 1994, Exercise and sport sciences reviews,
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
January 1983, Acta medica Scandinavica. Supplementum,
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
May 1988, Clinical pharmacology and therapeutics,
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
July 1999, Journal of applied physiology (Bethesda, Md. : 1985),
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
July 1988, American journal of hypertension,
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
August 2004, Journal of applied physiology (Bethesda, Md. : 1985),
J Cleroux, and P Van Nguyen, and A W Taylor, and F H Leenen
January 1993, European journal of clinical pharmacology,
Copied contents to your clipboard!